New Developments in Cervical Cancer Screening and Prevention

Section 1: Epidemiology and Public Health Aspects of Cervical Cancer:; Human Papillomavirus and Cervical Cancer: Epidemiological Evidence; Epidemiology of Cervical Human Papillomavirus Infection; Geographical and Social Patterns of Cervical Cancer Incidence; The Male Role in Cervical Carcinogenesis: Lessons from the Studies in Colombia and Spain and a Challenge for the Future; Statistical Issues in Studies of Human Papillomavirus Infection and Cervical Cancer; The Epidemiological Basis for Evaluating Screening Policies; Prevention Measures in the Third World: Are they Practical?; Prevention of Sexually Transmitted Infections through Health Education and Counselling: A General Framework; Section 2: Natural History and Management of Cervical Cancer Precursors: Biological Behaviour of Cervical Intraepithelial Neoplasia; Optimal Management of Cervical Cancer Precursors: Low Grade Squamous Intraepithelial Lesions; Optimal Management of Cervical Cancer Precursors: High-Grade Lesions; Glandular Lesions: An Increasing Problem; Papillomavirus Infection and Neoplasia in Women Infected with Human Immunodeficiency Virus; Section 3: The Cervical Cytology Paradigm: Performance of Cytology in Screening for Precursor Lesions and Early Cancer of the Uterine Cervix; The Bethesda System (TBS): Advantages and Pitfalls; Quality Assurance in Cervical Cytopathology; Error Rates in Cervical Cancer Screening: Causes and Consequences; Cervical Cancer Following Negative Smears; Section 4: Cytology Screening Programmes: Organization, Monitoring and Use of Resources for Screening Programmes; Cervical Screening by General Practitioners and Nurses and Information Feedback Systems; Screening Programmes: Results and Expectations; Screening for Cervical Cancer: Experience of the Nordic Countries; Screening that Failed to Work; Implementation and Evaluation of Cervical Cancer Screening Programmes in the European Union; Organization and results of Cervical Cancer Screening in Europe Over the Past 20 Years; Spontaneous Screening: Benefits and Limitations; Is Cervical Cancer Cytological Screening Valuable in Developing Countries?; Screening in Cervical Cancer Prevention in Porto Alegre, Brazil: The Experience of a Programme in a Developing Country; Section 5: Automation in Cytology: Automation and Cervical Cytopathology: An Overview; Automation in Cervicovaginal Cytology: System Requirements and Benefits; Automated Screening using the AutoPap 300 Device; Liquid-based Cytology: Comparison of ThinPrep 2000 with Conventionally Prepared Pap Smears; The History of Neural Network Technology in Cytology; A Comparison of Automated and Manual Screening: Theoretical Considerations; Cooperation of the Image Analyser and the Cytologist; Advantages and Limitations of Automated Screening Systems in Developing and Developed Countries; Section 6: Human Papillomavirus Testing: Methods of DNA Hybridization and their Clinical Applicability to Human Papillomavirus Detection; Human Papillomavirus Testing for Primary Cervical Cancer Screening; Human Papillomavirus DNA Testing Using Liquid-based Cytology; Human Papillomavirus Testing for Diagnostic Triage of Minor-grade Cytological Abnormalities: The European Perspective; Use of Human Papillomavirus Tying for Quality Assurance of Cytological Diagnosis; Estimates of the Cost Impact of Introducing Human Papillomavirus Testing into a Cervical Screening Programme; Viral Load as a Surrogate for Persistence in Cervical Human Papillomavirus Infection; Molecular Variant Analysis as a Tool in Natural History Studies of Human Papillomavirus Infection and Cervical Neoplasia; Section 7: Adjunct Screening Tests: Evaluation of Multiple Screening Techniques in a High-risk Area: The Guanacaste Project; Colposcopy as a Screening Tool for Cervical Cancer Detection: A Review; Adjuvant Tests to Cytology: Cervicography and the Polarprobe; Visual Inspection as a Screening Test for Cervical Cancer Control in Developing Countries; Section 8: Prevention and Therapy by Immunization: Human Papillomavirus Vaccines and Their Potential use in the Prevention and Treatment of Cervical Neoplasia; Animal Models for Evaluation of Human Papillomavirus Vaccines; Induction of Human Papillomavirus-Specific Immune Response; Section 9: Summary of Presentations and Consensus: Rapporteurs' Summary and Presentations; Highlights and Consensus; Index